Tech Company Financing Transactions
Epsilogen Funding Round
Epsilogen, based in London, raised $41.2 million from Novartis Venture Fund, British Patient Capital and Caribou Asset Management.
Transaction Overview
Company Name
Announced On
3/2/2022
Transaction Type
Venture Equity
Amount
$41,200,000
Round
Series B
Investors
Novartis Venture Fund (Lead Investor) (Marianne Uteng)
Epidarex Capital (Peter Finan)
Proceeds Purpose
The proceeds from the financing will enable Epsilogen to establish clinical proof of concept for lead drug candidate MOv18 IgE in a phase Ib trial in platinum-resistant ovarian cancer, an aggressive cancer with poor treatment alternatives.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
London BioScience Innovation Centre 2 Royal College St.
London, NW1 0NH
UK
London, NW1 0NH
UK
Phone
Website
Email Address
Overview
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Timothy Wilson
Chief Financial Officer
Ian Ardill
Chief Scientific Officer
Kevin FitzGerald
Browse more venture capital transactions:
Prev: 3/2/2022: The Host Co. venture capital transaction
Next: 3/2/2022: Tastewise venture capital transaction
Share this article
Where The Data Comes From
We report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs